全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

益生菌干预幽门螺杆菌感染者的观察性研究
An Observational Study on the Intervention of Probiotics in Patients with Helicobac-ter-Pylori Infection

DOI: 10.12677/HJFNS.2022.111010, PP. 80-86

Keywords: 幽门螺杆菌，益生菌，人体代谢
Helicobacter Pylori, Probiotics, Metabolism

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：近年来，幽门螺杆菌(Hp)根治方案不断引起关注。本研究旨在通过对Hp阳性患者进行益生菌(罗伊氏乳杆菌DSM17648)干预，观察干预前后人体成分指标以及生化代谢指标的变化，探索Hp感染与人体代谢的相关性，为Hp感染及其相关疾病患者的诊疗提供新思路。方法：自身对照临床观察性研究，对无症状体检但13C尿素呼气试验阳性者，给予1个月的常规饮食控制、生活方式指导建议、以及益生菌(罗伊氏乳杆菌DSM17648)干预，未给予其他抗Hp治疗，观察受试者干预前后：尿素呼气试验13C的变化，干预前后人体成分指标(体重、脂肪量、骨骼肌量、水分等)、以及生化代谢指标(血糖、甘油三酯、总胆固醇、高密度脂蛋白等)，分析Hp感染与上述指标的相关性。结果：纳入22例体检13C尿素呼气试验阳性者，完成研究资料完整共15人。所有纳入者采用同一个益生菌干预方案。干预28 ± 7天后，干预前后13C呼气试验平均值；36.5 ± 23.5 vs. 33.2 ± 22.2，其中三例复查13C呼气试验阴性，干预期结束一月后随访仍是阴性。干预前后人体指标：体重平均值：60.0 ± 13.1 kg vs. 60.3 ± 12.9 kg；脂肪平均值：15.1 ± 5.9 kg vs. 15.8 ± 6.4 kg；骨骼肌平均值：28.8 ± 6.6 kg vs. 30.1 ± 7.3 kg。生化指标：总胆固醇：5.5 ± 2.4 mmol/l vs. 4.8 ± 0.7 mmol/l；高密度脂蛋白：1.5 ± 0.4 mmol/l vs. 2.3 ± 0.8 mmol/l (p = 0.002 < 0.05)。干预前13C呼气试验数值与血糖值相关性分析p = 0.043 (<0.05)。结论：Hp感染者给予益生菌(罗伊氏乳杆菌DSM17648)干预后，13C呼气试验指标下降，人体指标、生化指标均有变化；患者Hp感染与血糖有一定的相关性，对Hp感染者及其相关疾病均有启发指导意义。
Objective: Recently, the radical treatment of Helicobacter pylori (Hp) has attracted more and more attention. The purpose of this study is to observe the changes of human composition indexes and biochemical metabolism indexes after the intervention of probiotics (Lactobacillus reuteri DSM17648) in Hp patients, and explore the correlation between Hp infection and metabolism, and provide new ideas for the diagnosis and treatment of patients with Hp infection and related diseases. Methods: This was a self-controlled clinical observational study. Humans who were physical examination but positive 13C urea breath test were given diet control, lifestyle guidance and probiotic (Lactobacillus reuteri DSM17648). After the intervention of one month, and without other Anti-Hp treatment. The changes of 13
References

[1]  Giulia, C. and Giulia, F. (2021) The Role of the Occupational Physician in Controlling Gastric Cancer Attributable to Helicobacter pylori Infection: A Review. Preventive Medicine Reports, 24, Article ID: 101527.
https://doi.org/10.1016/j.pmedr.2021.101527
[2]  Gravina, A.G., Zagari, R.M., De Musis, C., Romano, L., Loguercio, C. and Romano, M. (2018) Helicobacter pylori and Axtragastric Disease: A Review. World Journal of Gas-troenterology, 24, 3204-3221.
https://doi.org/10.3748/wjg.v24.i29.3204
[3]  El-Serag, H.B., Kao, J.Y., Kanwal, F., Gilger, M., LoVecchio, F., Moss, S.F., et al. (2018) Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 16, 992-1002.
https://doi.org/10.1016/j.cgh.2018.03.013
[4]  Liou, J.M., Malfertheiner, P. Lee, Y.C., Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM), et al. (2020) Screening and Eradication of Helicobacter pylori for Gastric Cancer Prevention: The Taipei Global Consensus. Gut, 69, 2093-2112.
https://doi.org/10.1136/gutjnl-2020-322368
[5]  Rokkas, T., Georgopoulos, S., Michopoulos, S., Ntouli, V., Liatsos, C., Puig, I., et al. (2021) Assessment of First-Line Eradication Treatment in Greece: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Annals of Gastroenterology, 34, 1-6.
https://doi.org/10.20524/aog.2021.0670
[6]  Busjahn, A., Jordan, D., Meling, H., Holz, K., Aria, S. and Lang, C. (2015) Decreasing of Quantity of Helicobacter pylori Using Lactobacilus reuteri DSMZ17648. Attending Physician, 2, 52-56.
[7]  Jastrz？b, R., Graczyk, D. and Siedlecki, P. (2021) Molecular and Cellular Mechanisms Influenced by Post-biotics. International Journal of Molecular Sciences, 22, Article ID: 13475.
https://doi.org/10.3390/ijms222413475
[8]  Ivashkin, V.T., Mayev, I.V., Trukhmanov, A.S., Lapina, T.L., Storonova, O.A., Zayratyants, O.V., et al. (2012) Recommendations of the Russian Gastroenterological Association for the Diagnosis and Treatment of Helicobacter pylori Infection in Adults. Russian Journal of Gastroenterology, Hepatol-ogy, Coloproctology, 30, 87-89.
[9]  Dajani, A.I., Abu Hammour, A.M., Yang, D.H., Chung, P.C., Nounou, M., Yuan, K.T.Y., Zakaria, M.A. and Schi, H.S. (2013) Do Probiotics Improve Response to Standardized or Sequential Therapy? Saudi Journal of Gastroenterology, 19, 113-120.
https://doi.org/10.4103/1319-3767.111953
[10]  王金坤, 袁丽萍, 李欢, 肖红云. 幽门螺杆菌感染胃炎患儿胃黏膜ASICs表达在胃肠道动力中的作用[J]. 实用医学杂志, 2021, 37(6): 755-758.
[11]  Miao, R., Wan, C. and Wang, Z. (2020) The Relationship of Gastric Microbiota and Helicobacter pylori Infection in Pediatrics Population. Helicobacter, 25, Article ID: e12676.
https://doi.org/10.1111/hel.12676
[12]  Tang, M.Y.L., Chung, P.H.Y., Chan, H.Y., Tam, P.K.H. and Wong, K.K. (2019) Recent Trends in the Prevalence of Helicobacter Pylori in Symptomatic Children: A 12-Year Retrospective Study in a Tertiary Center. Journal of Pediatric Surgery, 54, 255-257.
https://doi.org/10.1016/j.jpedsurg.2018.10.079
[13]  Tierney, B.T., Yang, Z., Luber, J.M., Beaudin, M., Wibowo, M.C. and Baek, C. (2019) The Landscape of Genetic Content in the Gut and Oral Human Microbiome. Cell Host & Mi-crobe, 26, 283-295.
https://doi.org/10.1016/j.chom.2019.07.008
[14]  Cortés-Martín, A., Selma, M.V., Tomás-Barberán, F.A., Gonzá-lez-Sarrías, A. and Espín, J.C. (2020) Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Molecular Nutrition & Food Research, 64, Article ID: 1900952.
https://doi.org/10.1002/mnfr.201900952
[15]  Vieira, A.T., Fukumori, C. and Ferreira, C.M. (2016) New Insights into Therapeutic Strategies for Gut Microbiota Modulation in Inflammatory Diseases. Clinical & Translational Immu-nology, 5, Article No. e87.
https://doi.org/10.1038/cti.2016.38
[16]  Azad, M.A.K., Sarker, M. and Wan, D. (2018) Immunomodulatory Ef-fects of Probiotics on Cytokine Profiles. BioMed Research International, 2018, Article ID: 8063647.
https://doi.org/10.1155/2018/8063647
[17]  Ganji-Arjenaki, M. and Rafieian-Kopaei, M. (2018) Probiotics Are a Good Choice in Remission of Inflammatory Bowel Diseases: A Meta-Analysis and Systematic Review. Journal of Cel-lular Physiology, 233, 2091-2103.
https://doi.org/10.1002/jcp.25911
[18]  Qi, D., Nie, X.L. and Zhang, J.J. (2020) The Effect of Probiotics Supple-mentation on Blood Pressure: A Systemic Review and Meta-Analysis. Lipids in Health and Disease, 19, Article No. 79.
https://doi.org/10.1186/s12944-020-01259-x
[19]  Drago, L. (2019) Probiotics and Colon Cancer. Microorganisms, 7, Article No. 66.
https://doi.org/10.3390/microorganisms7030066
[20]  Li, W., Guo, J., Shen, Y., Huang, L., Leng, B., Fan, D., et al. (2020) Probiotics, Prebiotics, and Synbiotics for the Treatment of Dementia: Protocol for a Systematic Review. Medicine, 99, Article No. e18608.
https://doi.org/10.1097/MD.0000000000018608
[21]  Uspensky, Yu.P. and Baryshnikova, N.V. (2015) Treatment of Helicobacter pylori Infection: Problems and Prospects. Consilum Medicum. Gastroenterology, 1, 8-17.
[22]  Parolova, N.I., Kornienko, E.A., Antonov, P.V., Egorov Mikhail Gorbunov, E.F. and Dmitrienko, M.A. (2015) An Innovative Approach to Infection H. pylori in Children. Russian Medical Journal, 22, 1339-1340.
[23]  Uspenskiy, Y.P., Fomin, Y.А., Ivanov, S.V. and Menaker, I.O. (2016) Evolution in Eradication Therapy of Hp-Associated Diseases: Beyond the Standards? Russian Medical Journal, 17, 1152-1153.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133